Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Enteryx

This article was originally published in The Gray Sheet

Executive Summary

Gastroesophageal reflux disease treatment gains newly assigned CPT code, permitting reimbursement under the hospital outpatient prospective payment system in 2004. The liquid polymer earned FDA approval in April (1"The Gray Sheet" April 28, 2003, p. 6)...

You may also be interested in...



Enteryx reimbursement

Results from Boston Scientific's ongoing U.S. and European gastrointestinal reflux disease treatment randomized placebo studies will be used to obtain private payor coverage. The 60-patient European study completed enrollment March 3, and enrollment for the 120-patient U.S. study is expected to conclude this summer. Both trials feature equal-sized treatment and placebo arms, with one-, three- and 12-month follow up. Enteryx recently received a CPT code for Medicare outpatient payment (1"The Gray Sheet" Nov. 24, 2003, In Brief)...

Boston Scientific Enteryx GERD Device Clears FDA With Limited Indication

Patients who respond to pharmacological treatments for gastroesophageal reflux disease (GERD) have a new therapeutic alternative in Boston Scientific's Enteryx injectable treatment system

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

MT019354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel